Brian A. Whiteman

Array ( [id] => 20762856 [patent_doc_number] => 20260159835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-06-11 [patent_title] => OLIGONUCLEOTIDE-MEDIATED KNOCKDOWN OF DUX4 [patent_app_type] => utility [patent_app_number] => 19/410976 [patent_app_country] => US [patent_app_date] => 2025-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 64638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19410976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20541247 [patent_doc_number] => 20260048135 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-02-19 [patent_title] => COMPOSITIONS AND METHODS OF USING PRKAG2-TARGETING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES [patent_app_type] => utility [patent_app_number] => 19/376782 [patent_app_country] => US [patent_app_date] => 2025-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42672 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19376782 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20006026 [patent_doc_number] => 20250144248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => METHODS AND SYSTEMS FOR IMPROVED NUCLEIC ACID DELIVERY VIA ULTRASOUND [patent_app_type] => utility [patent_app_number] => 18/937809 [patent_app_country] => US [patent_app_date] => 2024-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31337 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18937809 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19847054 [patent_doc_number] => 20250092405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => METHODS OF TREATMENT OF SCN2A-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 18/885261 [patent_app_country] => US [patent_app_date] => 2024-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21910 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 193 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18885261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20401297 [patent_doc_number] => 12491257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-12-09 [patent_title] => Compositions and methods of using PRKAG2-targeting antibody-oligonucleotide conjugates [patent_app_type] => utility [patent_app_number] => 18/755579 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 39 [patent_no_of_words] => 41761 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18755579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556809 [patent_doc_number] => 20240368601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => NCOVSIRNA DRUG FOR TARGETED DELIVERY SHRNA by RBD, SYNTHESIS METHOD, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/661524 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464516 [patent_doc_number] => 20240318185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => MESENCHYMAL STEM CELL-DERIVED MICRORIBONUCLEIC ACID-MEDIATED TREATMENTS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS [patent_app_type] => utility [patent_app_number] => 18/607162 [patent_app_country] => US [patent_app_date] => 2024-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607162 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19984031 [patent_doc_number] => 20250122253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => REGULATING MICROTUBULE DYNAMICS AS A THERAPEUTIC TARGET FOR NERVE REPAIR [patent_app_type] => utility [patent_app_number] => 18/437404 [patent_app_country] => US [patent_app_date] => 2024-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12126 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18437404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332865 [patent_doc_number] => 20240247295 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => METHOD FOR PRECISELY PREPARING CIRCULAR RNA WITH ANABAENA INTRON SELF-CLEAVING RIBOZYME [patent_app_type] => utility [patent_app_number] => 18/430378 [patent_app_country] => US [patent_app_date] => 2024-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 354 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18430378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432907 [patent_doc_number] => 20240301405 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => GUIDE RNAS FOR CRISPR/CAS EDITING SYSTEMS [patent_app_type] => utility [patent_app_number] => 18/418751 [patent_app_country] => US [patent_app_date] => 2024-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46058 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18418751 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19479793 [patent_doc_number] => 20240327835 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-03 [patent_title] => METHODS FOR REACTIVATING GENES ON THE INACTIVE X CHROMOSOME [patent_app_type] => utility [patent_app_number] => 18/417527 [patent_app_country] => US [patent_app_date] => 2024-01-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586785 [patent_doc_number] => 20240384342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => MATERIALS AND METHODS FOR CONTROLLING GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 18/403257 [patent_app_country] => US [patent_app_date] => 2024-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18403257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19249082 [patent_doc_number] => 20240200069 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => Synthetic Near-Threshold Translational Repressors [patent_app_type] => utility [patent_app_number] => 18/403466 [patent_app_country] => US [patent_app_date] => 2024-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12816 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18403466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19098126 [patent_doc_number] => 20240117354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES [patent_app_type] => utility [patent_app_number] => 18/542970 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19098133 [patent_doc_number] => 20240117361 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES [patent_app_type] => utility [patent_app_number] => 18/542975 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18542975 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19158054 [patent_doc_number] => 20240150761 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Modified Guide RNAs Comprising an Internal Linker for Gene Editing [patent_app_type] => utility [patent_app_number] => 18/532127 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -160 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19449246 [patent_doc_number] => 20240309376 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/532995 [patent_app_country] => US [patent_app_date] => 2023-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18532995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389782 [patent_doc_number] => 20240279652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => RNAi AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES [patent_app_type] => utility [patent_app_number] => 18/509440 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44660 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19158058 [patent_doc_number] => 20240150765 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => MERCAPTOPURINE-MODIFIED MIRNA FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/504849 [patent_app_country] => US [patent_app_date] => 2023-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18504849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19067587 [patent_doc_number] => 20240102013 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-28 [patent_title] => Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors [patent_app_type] => utility [patent_app_number] => 18/485592 [patent_app_country] => US [patent_app_date] => 2023-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60849 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18485592 [rel_patent_id] =>[rel_patent_doc_number] =>)